Epocrates has been a fixture in physician pockets since the PDA era, launching in 1998 as one of the first mobile drug reference tools. Now owned by athenahealth, it remains one of the most downloaded medical apps in the U.S., with over 1 million active healthcare professional users. The free tier provides drug monographs, an interaction checker, and pill identification — features that keep it installed on most residents' phones.
In our 2026 testing, Epocrates excelled at rapid drug lookups and interaction checks. The mobile app is fast and well-designed for point-of-care use. However, the platform has not meaningfully expanded into AI-assisted clinical reasoning. The disease content in the Plus tier is adequate but lacks the depth of UpToDate or DynaMed. There is no AI differential diagnosis engine, no natural-language query support, and no evidence synthesis.
At $174.99/year for Plus, pricing is reasonable compared to competitors, and the free tier is genuinely useful. But physicians looking for AI-powered decision support beyond drug reference will find Epocrates limited. It does one thing well — pharmacology at the point of care — but the market has moved toward broader clinical AI platforms.